Get the Stockscreener App
98.07
1.97%
-1.97
Pre-market:
97.01
-1.06
-1.08%
Incyte Corp stock is traded at $98.07, with a volume of 1.64M.
It is down -1.97% in the last 24 hours and down -2.82% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$100.04
Open:
$98.48
24h Volume:
1.64M
Relative Volume:
0.84
Market Cap:
$19.52B
Revenue:
$4.81B
Net Income/Loss:
$1.19B
P/E Ratio:
16.45
EPS:
5.961
Net Cash Flow:
$1.17B
1W Performance:
-2.95%
1M Performance:
-2.82%
6M Performance:
+12.78%
1Y Performance:
+39.58%
1-Day Range:
$97.00
$99.57
1-Week Range:
$97.00
$101.77
52-Week Range:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
98.07 | 19.91B | 4.81B | 1.19B | 1.17B | 5.961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Teachers Retirement System of The State of Kentucky Has $30.18 Million Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at TD Cowen Conference: Strategic Growth Beyond Jakafi - Investing.com
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
TD Asset Management Inc Increases Position in Incyte Corporation $INCY - MarketBeat
Incyte to Present at Three March Investor Conferences - MyChesCo
INCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Incyte (INCY) Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential - simplywall.st
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Lilly and Incyte’s Olumiant Recommended in EU for Adolescents with Severe Alopecia Areata - Contract Pharma
Hair-loss pill helps 42% of teens regrow scalp hair in Lilly trial - Stock Titan
Andra AP fonden Boosts Stake in Incyte Corporation $INCY - MarketBeat
NICE backs approval for Incyte’s Opzelura - The Pharma Letter
Incyte Earnings Underscore Shift From Jakafi Reliance To Broader Pipeline - Yahoo Finance
INCYTE (INCY) R&D president exercises options, sells 18,668 shares at $100.91 - Stock Titan
Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals - ChartMill
Incyte Stock Fell 7% Last Week. Here’s What the Rest of 2026 Could Look Like - TIKR.com
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales - Finviz
Aberdeen Group plc Grows Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Reports $5.14 Billion in 2025 Revenue, Issues 2026 Outlook - MyChesCo
Where is Incyte Corporation (INCY) Headed According to Analysts? - Finviz
Barclays Analyst Raises Price Target for Incyte (INCY) to $117 | - GuruFocus
Incyte (INCY) Expands Latin American Partnership with Knight The - GuruFocus
The Top 5 Analyst Questions From Incyte's Q4 Earnings Call - Finviz
Incyte to Present at Upcoming Investor Conferences - Business Wire
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call - Yahoo Finance
Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally? - Smartkarma
Do Wall Street analysts like Incyte Corporation stock? - MSN
INCY Q4 earnings miss estimates, revenues beat on higher product sales - MSN
Cookson Peirce & Co. Inc. Acquires Shares of 11,331 Incyte Corporation $INCY - MarketBeat
Incyte’s weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10) By Reuters - Investing.com
Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Is It Too Late To Consider Incyte (INCY) After Its 43% One Year Rally - Yahoo Finance
Incyte Corporation $INCY Shares Sold by Sound Shore Management Inc CT - MarketBeat
LSV Asset Management Buys 124,266 Shares of Incyte Corporation $INCY - MarketBeat
Illinois Municipal Retirement Fund Sells 15,073 Shares of Incyte Corporation $INCY - MarketBeat
Do Wall Street Analysts Like Incyte Corporation Stock? - Barchart.com
INCY: Stifel Raises Price Target to $120, Maintains Buy Rating | - GuruFocus
Incyte shifts course on downtown Wilmington project, sells Bracebridge buildings as state incentives face scrutiny - Delaware LIVE News
Incyte selling buildings and cutting back space at future downtown headquarters - Delaware Business Now
Do financial experts on Wall Street have a favorable opinion of Incyte Corporation shares? - Bitget
Incyte selling buildings and cut back space at future downtown headquarters - Delaware Business Now
Royal Bank Of Canada Cuts Incyte (NASDAQ:INCY) Price Target to $92.00 - MarketBeat
Incyte (INCY): RBC Capital Lowers Price Target to USD 92 | INCY Stock News - GuruFocus
Incyte (INCY) Analyst Ratings Update: Wells Fargo Lowers Price T - GuruFocus
Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00 - MarketBeat
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow - Finviz
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Call Transcript - Insider Monkey
INCY: HC Wainwright & Co. Reiterates Buy Rating, Maintains $135 Price Target | INCY Stock News - GuruFocus
Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation - Citeline News & Insights
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):